NCT02350218View on ClinicalTrials.gov

Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)

PHASE2UnknownINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Evidence of Liver Transplantation
Interventions
DRUG

Eglandin

Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient

Trial Locations (1)

138-736

Korea, Republic of, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER